Eli Lilly Reports Soaring Q1 Revenue & EPS, Raises Full-Year Guidance, and Secures Key FDA Approval

summarizeSummary

Eli Lilly reported outstanding Q1 2026 financial results with substantial revenue and EPS growth, raised its full-year guidance, and announced FDA approval for its new oral GLP-1 obesity drug, Foundayo.

check_boxKey Events

• Exceptional Q1 Financial Performance

  Revenue increased 56% to $19.8 billion, and reported EPS surged 170% to $8.26, driven by strong volume growth from Mounjaro and Zepbound.

• Raised Full-Year Guidance

  The company increased its 2026 full-year revenue guidance to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00.

• FDA Approval of Foundayo

  Received U.S. FDA approval for Foundayo (orforglipron), an oral GLP-1 pill for adults with obesity, offering a new, convenient treatment option.

• Robust Pipeline Progress

  Announced positive Phase 3 results for Foundayo in type 2 diabetes, Jaypirca in CLL/SLL, Taltz and Zepbound combination for psoriasis/obesity, and retatrutide in type 2 diabetes.

auto_awesomeAnalysis

Eli Lilly delivered an exceptionally strong first quarter, significantly exceeding expectations with robust revenue and earnings growth driven by its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. The company's decision to raise its full-year revenue and EPS guidance signals continued confidence in its growth trajectory. Furthermore, the FDA approval of Foundayo, a new oral GLP-1 pill for obesity, represents a major strategic win, potentially expanding market access and solidifying Lilly's leadership in the metabolic health space. Investors should note the broad-based positive developments, including significant pipeline advancements and strategic acquisitions, which collectively reinforce a strong long-term outlook for the company.